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Background: To investigate the association and magnitude of risk between JIA, its associated treatment and cancer
development in Taiwanese children.
Methods: Nationwide population-based 1:4 age- and gender-matched retrospective cohort study was designed
using the National Health Insurance Research Database of Taiwan. A cohort of 2,892 children <16 years old with JIA
was formed as well as a non-JIA cohort of 11,568 in year 2003 to 2005. They were followed up till a diagnosis of
malignancy or up to 8 years until 2010. Relative risk (RR), incidence rate ratio (IRR), and adjusted hazard ratio (aHR)
of developing malignancy were calculated.
Results: The female to male ratio was 0.79:1. There were 3 cases of incident cancer in the “MTX use, biologics-naïve”
group, only 1 in the anti-TNF biologics-containing group and 29 in the “both MTX- and biologics-naïve” group, in
comparison, there were 50 cases of cancer in the non-JIA comparator group. During a 16114.16 patient-years
follow-up, the RR and IRR for developing a malignancy in both methotrexate- and anti-tumor necrosis factor (TNF)
biologics-naïve JIA children were 2.75 (95% confidence interval, 1.75 – 4.32) and 3.21 (2.01 – 5.05), respectively. For
leukemia, the IRR was 7.38 (2.50 – 22.75); lymphoma, 8.30 (1.23 – 69.79); and soft tissue sarcoma, 11.07 (0.84 – 326.4).
The IRR of other cancers was 2.08 (1.11 – 3.71). The aHR on cancer risk was 3.14 (1.98 – 4.98) in methotrexate- and
biologics-naïve group. There were no statistically significant increased risk in JIA patients treated with methotrexate
and/or anti-TNF biologics.
Conclusions: Compared with children without JIA, children with JIA have 3-fold increase of risk on malignancy in East
Asia. Seemingly neither methotrexate nor anti-TNF biologics increases the risk further.
Keywords: Arthritis, Juvenile rheumatoid (MeSH), Juvenile idiopathic arthritis, Neoplasms (MeSH), Risk (MeSH), Cohort
studies (MeSH)Background
Juvenile idiopathic arthritis (JIA) is a spectrum of several
heterogeneous disorders manifested mainly as chronic
inflammatory arthritis with no identifiable etiology with
an onset before the age of 16 years. The older terms,
juvenile rheumatoid arthritis (JRA) and juvenile chronic
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unless otherwise stated.idiopathic arthritis which is a more inclusive term than
JRA [1].
Approximately 1 in every 1000 children worldwide has
JIA [2,3]. The best available annual incidence rate for
JIA in the West is from a UK study which provided an
estimate at 10/100,000 [4]. JIA appears to be less com-
mon in African-American and Asian populations [5]. A
population-based study in Taiwan demonstrates that the
prevalence of JIA in Taiwan is 3.7/100,000, which is
higher than the prevalence in Japan, but lower than that
in the West [6]. In addition to this ethnic difference in
prevalence, previous studies revealed that the age of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Caucasians and Asian children [6-8]. In our previously
reported community-based cohort study of the clinical fea-
tures in children with JIA in selected regions of Taiwan
using the International League of Associations for Rheuma-
tology system (ILAR) classification criteria, a remarkably
high prevalence was found in the enthesitis-related arthritis
(ERA; 37.4%) of the Chinese cohort, but a relatively low
rate of uveitis (6.7%) as compared with previous reports on
Western populations [9].
The first line treatment for JIA usually contains nonste-
roidal antiinflammatory drugs (NSAIDs) and/or intraarticu-
lar glucocorticoid injection for controlling inflammation.
Disease-modifying antirheumatic drugs (DMARDs), usually
used in second line, are comprised of methotrexate (MTX)
(conventional) and tumor necrosis factor (TNF-alpha)
inhibitors (biologics) [10-14]. The criteria for escal-
ation of therapy can be found in the paper published
by the American College of Rheumatology elaborating
the evidence-based recommendations for the treatment of
JIA [15].
Two recent reports, one from the Canadian JIA regis-
tries maintained by paediatric rheumatology centers (JIA
children = 1,834) and another from a Scottish nationwide
population-based inpatient cohort (n = 349), showed no
increase of risk for cancer over long-term follow-up
[16,17]. Nevertheless, three other recent studies notably
showed increased risks of malignancy in patients with
JIA [18-20].
Therefore, the aim of the present study was to esti-
mate the magnitude of the risk of cancer in East Asian
population of JIA and to examine the risk of cancer in




This study was designed as a population-based retrospect-
ive cohort study using data from a national administrative
database with 1:4 gender- and age-matched comparators
followed up to 8 years or until a diagnosis of malignancy
was given. Figure 1 is a study flow chart demonstrating
the design.
Study population
The study population was targeted from the Taiwan
National Health Insurance Research Database (NHIRD).
The NHIRD has been described in-depth in our previous
studies [6,21-26]. In short, Taiwan National Health In-
surance (NHI) program commenced on 1 March 1995.
As of 2007, 98.4% of Taiwan’s population (22.96 million
individuals) were enrolled in this program. The NHIRD
provided to researches for academic research purposes
contains a number of large computerized databases thatincorporate registration files and relational original data on
claims’ reimbursement. These data files are de-identified
by scrambling the identification codes of both the indivi-
duals and medical facilities and access to the files including
data-mining and data-manipulation shall strictly comply
with the Taiwan Personal Information Protection Act.
Case definition and definition of diseases/conditions
In Taiwan, paediatric rheumatologists prefer to use the
ILAR classification criteria for making a diagnosis of JIA
[27]. Grouping of ICD-9-CM codes can be mapped to
the ILAR categories in patients under the age of 16:
714.2 (systemic arthritis), 714.30 + 714.31 (polyarthritis),
714.32 + 714.33 (pauciarthritis or oligoarthritis, persistent
and extended), 720.0 alone or (720.0 + 714.0) or (720.0 +
714.3) (ERA), 696.0 (psoriatic arthritis).
A diagnosis of JIA in this study requires 3 components,
age less than 16 years, at least 3 times of reimbursement
claims made by a paediatric rheumatologist(s) or a paedia-
trician(s) using any of the abovementioned ICD-9-CM
codes with the first and the third claim being 6 months
apart.
Study cohorts
From 2002 and 2010, we were able to identify all children
less than 16 years old that diagnosed with JIA (n = 7,254).
From these JIA children over a period of 9 years, we se-
lected 2,912 children with JIA in years 2003 to 2005. Then
children with JIA who had already been given a diagnosis
of malignancy were excluded (n = 20). The criterion for
this exclusion required only a single claim with a cancer
ICD-9-CM code traceable back to at least one whole year
in the medical record so that the accrual of patients were
actually having no prevalent cancer. This left a group of
children <16 years old with JIA but having no evidence of
malignancy (n = 2,892) which became the JIA cohort for
this study.
For forming a non-JIA comparator cohort, we did a
1:4 age- and sex-match for children with neither JIA nor
cancer diagnosis traceable to the previous one year from
the same period, 2003 to 2005. The index date for the
comparator cohort was the earliest claim record. The
non-JIA control group consisted 11,568 children.
Grouping of JIA patients by treatment modalities
In the period of 2003 to 2005, there were 2 kinds of
TNF-alpha inhibitor reimbursed by the NHI Taiwan for
children with JIA, namely, etanercept and adalimumab.
In the JIA cohort, three distinct groups could be sepa-
rated by treatment allocation: biologics-naïve methotre-
xate group, anti-TNF biologics-containing group, and
both methotrexate- and biologics-naïve group.
Treatment with TNF-alpha inhibitors was categorized as
ever exposed versus never exposed. Once exposure to a
Figure 1 Retrospective cohort study design and study flow chart. NHIRD: National Health Insurance Research Database Taiwan; JIA: Juvenile
idiopathic arthritis equivalent.
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was maintained during the study follow-up. The person-
time data for each therapeutic agent category did not
include the person-time before the commencement of
prescription of either MTX (in the biologics-naïve MTX
group) or TNF-alpha inhibitors. Basically, the group
being both methotrexate- and biologics-naïve can be
regarded as children with JIA having no exposure to
methotrexate or TNF-alpha inhibitors, thus the risk
factor can be considered to be the diagnosis of JIA.
Outcomes by identification of cancer cases
Each patient and control in the study was followed up to
a maximum of 8 years through the NHIRD from accrual
to identify whether the studied individual received a can-
cer diagnosis. The diagnostic accuracy of a specific kind
of malignancy was confirmed by both a specific ICD-9-
CM code within 140 to 208 given at least 3 times in
different medical visits and inclusion into the Registry
for Catastrophic Illness Patient Database (RCIPD). The
index date was set on the date of the firstly detected
code amongst three times claims using any one of the
JIA ICD-9-CM codes.
The scope and procedures of the search for the studies to
be considered in the systematic review
We conducted a systematic review of the literature on
the risk of cancer in children with JIA and whether the
risk would further be increased after exposure to
DMARDs. The criteria for inclusion of published studies
for the review were cohort studies examining risk of
cancer in terms of relative risks (RR), incidence rate ratio
(IRR), or standardized incidence ratio (SIR), in children
with JIA no matter receiving any kinds of treatment for
JIA. We performed literature search in PubMed and
DOAJ (the Directory of Open Access Journals) using
medical subject headings (MeSH) terms combined with
Boolean logics. The period of time covered by the litera-
ture search was from as early as the PubMed or DOAJ
has covered until September of 2013. Table 1 outlines
the result of this systematic review.
Statistical analysis
SAS statistical package (SAS System for Windows, version
8.2, SAS Institute, Cary, NC, USA), SPSSsoftware (version
17.0, IBM Inc., Chicago, Illinois, USA) and StatsDirect
statistical software (StatsDirect Ltd, England, 2008) were
used. The risk for cancer associated with JIA and various
DMARDs exposure was evaluated and presented as a cu-
mulative incidence ratio (RR) and HR in Cox regression.
The RR which will not be influenced by immortal time
was presented along with IRR. All statistical tests were
two-sided. Values of P < 0.05 were considered statistically
significant. Cox models providing adjusted HR (aHR)included age, gender, and treatment modality as covar-
iates. HRs with a 95% confidence interval were calcu-
lated. The RR of cancer development were calculated
and analyzed by Chi-square test (2×2). In addition, the
impact of risk factors (how much disease burden is
caused by certain risk factors) was also presented using
the population attributable risk percent (PAR%) with
95% confidence interval in certain conditions.
This study has been approved by the Ethics Committee
of Chang Gung Memorial Hospital Taiwan.Ethics statement
Because this study used only NHIRD data files that were
de-identified by scrambling the identification codes of
both individuals and medical facilities, this research
fits the criteria for exemption from a full review by the
Institution Review Board contained within the legal
statements promulgated by the Ministry of Health and
Welfare of Taiwan pursuant to Paragraph 1, Article 5 of
the Human Subjects Research Act enacted on December
28, 2011. This study adhered to strict confidentiality
guidelines that are in accordance with the regulations
set forth by the Personal Information Protection Act of
Taiwan, amended on May 26, 2010. The research was con-
ducted in accordance with the Declaration of Helsinki as
revised in 1989.Results
Demographic characteristics of the JIA cohort
In the JIA cohort (n = 2,892), there were 1,618 boys and
1,274 girls. The female to male ratio was 0.79: 1. Most of
the patients (n = 1,960, 67.8%) with JIA were in the age
group of 11-15, 699 (24.2%) in age group 6-10, and 233
(8%) were in age group 0-5 (Table 2). Our results
showed that the mean age of children with JIA assigned
to the anti-TNF biologics group (mean, 10.54 years)
were significantly younger than the other two groups,
namely, biologics-naïve MTX group with mean age at
11.22 and both MTX- and biologics-naive group, 11.55
(Table 3).
In the JIA cohort, 344 patients, approximately 12%,
were treated with methotrexate but were TNF-alpha
inhibitor-naïve. One hundred and twelve patients (3.9%)
required a TNF-alpha inhibitor to control their disease;
93.75% of them (n = 105) were previously or currently
treated with methotrexate. Forty patients (1.4%) of JIA
patients were treated with non-biologic DMARDs other
than methotrexate which can possibly be sulfasalazine,
hydroxychloroquine, leflunomide, azathioprine and/or
cyclosporin in this country (Table 3).
The mean duration of follow-up for the JIA cohort
was 6.40 (SD 1.44) years and 7.78 (SD 0.59) in non-JIA
cohort.
Table 1 Outline of the results of the systematic literature review of the risk of malignancy in individuals with juvenile idiopathic arthritis
Authors/Year
published









Beukelman T et al/2012 Using national Medicaid
data/7,812
SIR The SIR was 4.4 (95% CI, 1.8 – 9.0) for probable
and highly probable incident malignancies. The
unexposed (to both non-biologic and biologic
DMARDs) group: the SIR = 6.9 (2.3 – 16).
SIR = 3.9 (95% CI 0.4 – 14)
Following any use of
TNF inhibitors, SIR was
0 (95% CI 0 – 13).
20
Simard JF et al/2010 Nationwide cohort study through
linkage with the Swedish Patient
Register/5,296
RR Subjects with JIA (biologics-naïve) identified in 1987 beyond (n = 5,296)
was significantly associated with incident lymphoproliferative malignancies
(RR 4.2, 95% CI 1.7–10.7) and cancers overall (RR 2.3, 95% CI 1.2–4.4).
- 18
Nordstrom BL et al/2012 Large claims database American
cohort study/3,605
IR, SIR The IRs of probable or highly probable cancer: 67.0 (95% CI, 1.3 – 132.5)
cases/100,000 PY for biologics-naïve JIA and 23.2 (12.2 – 34.2) cases/100,000
PY for non-JIA. The JIA cohort had an elevated SIR of 4.0 (95% CI 2.6 – 6.0)
above SEER rate.
19
Kok VC et al/this study Nationwide population-based
Retrospective cohort study/2,892
RR, IRR The RR and IRR for developing a malignancy in
JIA individuals who were both MTX- and anti-TNF
biologics-naïve were 2.75 (95% CI, 1.75 – 4.32) and
3.21 (95% CI, 2.01 – 5.05), respectively, with the
population attributable risk of 23.38% (95% CI,
10.56 – 36.21). For leukemia, the RR was 6.33
(2.30 – 17.44); lymphoma, 7.12 (1.42 – 35.61); and
soft tissue sarcoma, 9.50 (1.24-72.46). The aHR on
cancer risk was 3.14 (1.98 – 4.98) in MTX- and
biologics-naïve group.
No further increase in risk No further increase
in risk
This study
Bernatsky S et al/2011 JIA registries at 3 Canadian
pediatric rheumatology
centers/1,834
SIR Only one invasive cancer was identified in individuals with JIA observed for
an average of 12.2 (SD 7.8) years (observation period: 1974 – 2006). SIR = 0.12
(95% CI, 0.0 – 0.7). The risk of invasive cancers overall is NOT increased. No
further information on its relationship to drug exposure.
16
Thomas E et al/ 2000 Scottish nationwide population-
based inpatient cohort/896
SIR SIR in boys JIA with 2,647 person-years at risk: 1.29 (95% CI, 0.14–4.64); girls JIA with 3,940
person-years at risk, 0.83 (95% CI, 0.09–3.01)./Not increased
- 17
CI: confidence interval; IR: incidence rate; IRR: incidence rate ratio; JIA: juvenile idiopathic arthritis; MTX: methotrexate; RR: relative risk; SIR: standardized incidence ratio; anti-TNF: anti-tumor necrosis factor. Selected

















Table 2 Demographic data of JIA and non-JIA children in this cohort study
JIA (n = 2,892) Non-JIA (n = 11,568)
Gender Boys 1,618 6,472
Girls 1,274 5,096
Female : male ratio 0.79 : 1 0.79 : 1
Age Group 0 - 5 233 932
6 - 10 699 2,796
11 - 15 1,960 7,840
Type of JIA by ILAR criteria
Polyarthritis 377 NA
Pauciarthritis or oligoarthritis (persistent and extended) 136 NA
Enthesitis-related arthritis 1221 NA
Psoriatic arthritis 62 NA
Systemic 6 NA
Unclassifiable 1096 NA
Years of follow-up Mean (SD) 6.40 (1.44) 7.78 (0.59)
Person-years at risk 18,530.97 89,156.74
Abbreviations: DMARDs: Disease modifying anti-rheumatic drugs; ILAR: the International League of Associations for Rheumatology; JIA: juvenile idiopathic arthritis;
MTX: methotrexate; NA: not applicable; SD: standard deviation; TNF: tumor necrosis factor.
It is noteworthy of the marked difference in male to female ratio in East Asian children as compared to Caucasians.
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Compared to non-JIA children during 89156.74 patient-
years at risk, children with JIA who were MTX- &
biologics-naïve during 16114.16 patient-years at risk
had significantly elevated RR for incident malignancy
associated with JIA and IRR at 2.75 (95% CI 1.75 – 4.32)
and 3.21 (95% CI 2.01 – 5.05), respectively. The cumula-
tive incidence of cancer was significantly higher in
MTX- & biologics-naïve JIA children group (1.19% vs.
0.43%, P <0.0001). The population attributable risk was
23.38% (95% CI, 10.56% – 36.21%) meaning among the
general population, somewhere between 11% to 36% of
the total risk for cancer was due to JIA status (Table 3).
With mean (SD) duration of follow-up of the JIA sub-
groups of “biologics-naïve methotrexate group” for 5.93
(2.08) years (2030.08 patient-years at risk), “anti-TNF
biologics-containing” 3.46 (1.82) years (386.73 patient-years
at risk), and “both methotrexate- and biologics-naïve”
6.60 (1.10) years (16114.16 patient-years at risk), we did
not observe a statistically significant increased risk for
cancer in JIA subgroups treated with methotrexate (RR
2.02; 95% CI, 0.67 – 6.04) or anti-TNF biologics (RR 2.07;
95% CI, 0.36 – 11.49) (Table 3). The mean duration of
drug exposure in years for methotrexate group was 2.97
(2.82) and for anti-TNF inhibitor-containing group 3.05
(1.75).
The indirect standardized incidence rate (SIR) for all
types of cancer in the non-JIA comparator cohort de-
fined as ((Observed number of malignancies/Expected
number of malignancies) × crude cancer incidence rate ofthe national population) was estimated. The crude cancer
incidence rate of the national population aged from ten
to twenty four years in the year 2008 was 17.10 per
100,000 as documented in the officially published
Taiwan Cancer Registry, “Table Seven: Age distribution
of cancer morphology by gender and primary anatomic
sites 2008” (http://tcr.cph.ntu.edu.tw/main.php?Page=N2).
The expected number of incident malignancies was three.
Thus, the indirect SIR for all types of cancer in the non-
JIA cohort equals 285 (50 / 3 × 17.1) per 100,000. It is
higher than the nationwide average age-specific incidence
rate for all types of cancer.
Based on the “both methotrexate- and biologics-naïve”
subgroup of 2,436 patients with JIA having a mean fol-
low up of 6.6 years, the incidence rate ratio for selected
cancer types were calculated. There were increased IRR
for leukemia at 7.38 (95% CI, 2.50 – 22.75), lymphoma
8.30 (95% CI, 1.23 – 69.79) and other malignancy mostly
solid tumor 2.08 (95% CI, 1.11 – 3.71). However, there
were no statistical increase of IRR in soft tissue sarcoma
at 11.07 (95% CI, 0.84 – 326.4) and primary bone cancer
5.53 (0.14 – 215.8) (Table 3).
Cox proportional hazard regression models
After adjustment for age and gender, the aHR for develop-
ing malignancy was 3.14 times higher (95% CI, 1.98 – 4.98,
P <0.0001) in children with JIA who had not been exposed
to either methotrexate or TNF-alpha inhibitors (Table 4).
There were no further statistically significant increase of
the risk in terms of aHR in children with JIA treated with









Total 344 112Ϯ 2436 11568
Gender Female 144 43 1087 5096 0.4849
Male 200 69 1349 6472
Mean age (SD) 11.22 (3.23) 10.54 (3.67) 11.55 (3.46) 10.94 (3.65) <0.0001
Age group (n) 0 – 5 20 12 201 932 0.0054‡
6 – 10 104 38 557 2796
11 – 15 220 62 1678 7840
Follow-up year, mean (SD) 5.93 (2.08) 3.46 (1.82) 6.60 (1.10) 7.78 (0.59) <0.0001
Duration of drug exposure in year,
mean (SD)
2.97 (2.82) 3.05 (1.75) NA NA 0.78
Malignancy Yes 3 1 29 50 <0.0001
No 341 111 2407 11518
Person-years 2030.08 386.73 16114.16 89156.74
Incidence rate ratio (95% CI) 2.64 (0.65-7.53) 4.61 (0.23-23.61) 3.21 (2.01-5.05) Ref
Relative Risk (95% CI) 2.02 (0.67-6.04) 2.07 (0.36-11.49) 2.75 (1.75-4.32)* Ref
Population attributable risk
(95% CI)
2.85% (-3.53-9.24) 1.01% (-2.82-4.84) 23.38% (10.56-36.21) Ref
Leukemia Yes 2 0 8 6
IRR (95% CI) - - 7.38 (2.50-22.75)* Ref
Lymphoma Yes 0 0 3 2
IRR (95% CI) - - 8.30 (1.23-69.79)* Ref
Soft tissue sarcoma Yes 0 0 2 1
IRR (95% CI) - - 11.07 (0.84-326.4) Ref
Primary bone cancer Yes 0 0 1 1
IRR (95% CI) - - 5.53 (0.14-215.8) Ref
Other malignancy Yes 1 1 15 40
IRR (95% CI) - - 2.08 (1.11-3.71)* Ref
CI: confidence interval; JIA: Juvenile idiopathic arthritis; MTX: methotrexate; NA: not applicable; Ref: reference; SD: standard deviation; TNF: tumor necrosis factor.
*statistically significant, P < 0.05.
Ϯ105 subjects (93.75%) previously or currently received MTX treatment.
‡: Kruskal-Wallis statistic.
Chi-square analysis-of-contingency table statistical method was for categorical data such as gender.
Poisson distribution and test-based methods are used to construct the confidence intervals for IRR.
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P = 0.0932) or TNF-alpha inhibitors whose aHR, 6.05
(95% CI, 0.82 – 44.61; P = 0.0772) (Table 4). It merits
mention that the anti-TNF biologics-containing group in
the JIA cohort contained only 112 children.Table 4 Cox proportional hazard regression model showing t
malignancy in different groups of JIA patients by treatment a
MTX use, biologics-naive Anti-TNF biologics-c
aHR 2.72 6.05
95% CI 0.85 – 8.73 0.82 – 44.61
P-value 0.0932 0.0772
aHR: adjusted Hazard Ratio by gender and age; CI: confidence interval; JIA: juvenileDiscussion
Through this nationwide population-based retrospective
cohort, we demonstrated that the incidence of malig-
nancy was significantly increased approximately 3-fold in
Taiwanese children with JIA. There were three cases ofhe adjusted hazard ratio on the risk of developing
nd non-JIA patients
ontaining Both MTX- and biologics-naive Non-JIA
3.14 1
1.98 – 4.98 -
<0.0001 -
idiopathic arthritis; MTX: methotrexate; TNF inhibitor: tumor necrosis factor.
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only one in the anti-TNF biologics-containing group and
twenty nine in the “both MTX- and biologics-naïve”
group, in comparison, there were fifty cases of cancer in
the non-JIA comparator group. The cancer types which
were found to be statistically increased in terms of the IRR
were leukemia (7-fold increase), lymphoma (8-fold) and
all other malignancies (2-fold).
To the best of our knowledge, this cohort study pre-
sents the first best available estimate of the magnitude of
risk for cancer in Asian JIA population. Our results in
East Asian children in addition to three other prior large
studies using claims database, National Medicaid data,
or the Swedish Patient Register National Data, suggest
that children with JIA per se is associated with a 2- to
4- fold increase of cancer risk, particularly lymphopro-
liferative malignancies (Table 1) [18-20]. However, our
data did not reveal statistically significant further increase
of incident malignancy in children with JIA after a mean
(SD) duration of exposure of 2.97 (2.82) years to metho-
trexate and/or 3.05 (1.75) years to TNF-alpha inhibitors.
Although anti-TNF biologics treatment are feared to in-
crease the risk of malignancy particularly lymphoprolifera-
tive malignancy such as hepatosplenic T-cell lymphoma
(HSTCL) which is the commonest reported subtype of
all T-cell lymphoma, this phenomenon is still not yet
confirmed in any published prospective cohort study
[20,28-33]. One of the explanations may be owing to
the inherent susceptible risk already exists in children
with JIA.
A recent detailed analysis of 100 cases of T-cell non-
Hodgkin’s lymphoma (NHL) reported to the US FDA
disclosed that 68% of the cases involved exposure to
both a TNF-alpha inhibitor and an immunomodulator. Risk
of T-cell NHL was higher with concomitant use of
TNF-alpha inhibitor with thiopurines (95% CI 4.98-
354.09; P < 0.0001) and thiopurines alone (95% CI
8.32-945.38; P < 0.0001) but not with TNF-alpha in-
hibitor use alone (95% CI 0.13-10.61; P = 1.00) [34].
Many of those reported cases that lead the FDA to place a
black box warning on TNF-alpha inhibitors were in chil-
dren with inflammatory bowel disease rather in JIA.
The female to male ratio in our JIA cohort was 0.79: 1.
This ratio echoes other prior studies from Asia that in
contrast to Caucasian population having female prepon-
derance which ranges from 2: 1 to 3: 1 in most published
series, Asian population of JIA has a relative male pre-
dominance. The explanation for this sex ratio difference
is fairly clear that ERA, an entity of predominantly male
and older age of onset, constituted 42% of the JIA cohort
in this study. Our previous study mentioned earlier in
the paper found that the proportion of ERA was 37.4%
in the Taiwanese Chinese cohort [9]. In addition, other
unique clinical features reported in Asian children areolder age of onset, a lower antinuclear antibody (ANA)
positivity rate, a lower chronic uveitis incidence and
different subtypes of JIA on presentation [5,6,9].
In the JIA cohort, 15.5% ((344 + 105) / 2,892) of children
required methotrexate for aggressive preservation of joint
function and control of disease process. And only 3.9% of
the entire JIA cohort were escalated to anti-TNF biologics
therapy. In a published nationwide retrospective survey of
570 cases in Japan, 12.8% of their case series were treated
with methotrexate [7]. This may reflect an overall real-
world picture of the severity and treatment policy for JIA
in East Asia.
Strengths and limitations
Our study has certain strengths. Because participation in
the NHI program is mandatory and all residents of
Taiwan can assess a paediatrician rheumatologist without
needing a referral, the referral bias is essentially avoided.
Loss to follow-up is virtually non-exist because of the
country-wide NHI coverage for medical care allowing
continuous tracking of an enrollee during relocation or
self-transferal. With a large number of age- and gender-
matched non-JIA comparators, the cumulative incidence
rate of cancer in the control group is considered accurate.
However, the findings of this study need to be inter-
preted in the context of certain potential limitations.
First, many demographic variables were not available,
such as family history of cancer, diet and environmental
exposures. This is because individual identities are not
available due to the de-identification of the individuals
within the NHI databases. Second, the disease severity of
JIA could not be obtained in this claims study. The risk of
over-diagnosis resulted from solely using the ICD-9-CM
codes for case identification is likely present due to inabil-
ity to verify the diagnosis of JIA using the patients’ own
medical records. We could not be 100% sure to exclude
potentially exist undiagnosed JIA cases in the control
group which may result in possible allocation bias. Finally,
since this is not an incidence cohort for JIA and left
censoring of disease and medication therapy cannot be
excluded.
The possibility of a protopathic bias was not completely
ruled out although the study design had deployed an
exclusion criteria to exclude subjects with pre-existing
cancer traceable back to at least one whole year in the
medical record by ICD-9-CM codes.
Conclusions
This nationwide population-based retrospective cohort
study of the association between JIA by their treatment
allocation and cancer risk with up to 8 years follow-up
reveals that this East Asian children population with JIA
is associated with a 3-fold increased risk of malignancy
(IRR = 3.21 and adjusted HR = 3.14) and there is no
Kok et al. BMC Cancer 2014, 14:634 Page 9 of 10
http://www.biomedcentral.com/1471-2407/14/634statistically significant increased risk in these patients
with exposure to methotrexate and/or TNF inhibitors.
The risk for other solid tumors was statistically signifi-
cantly increased by 2-fold.
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